Research

Mixed

Lower drug prices for semaglutide and tirzepatide could significantly improve their cost-effectiveness, potentially making them competitive with surgical and behavioral interventions.

If drug prices for semaglutide and tirzepatide were reduced, these medications could become cost-effective options for managing class III obesity, potentially offering a non-surgical alternative.

GoodConditionalHIGH confidence
Lower drug prices could significantly improve pharmacotherapy cost-effectiveness.
Nisha Gupta et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Based on scenario analyses using tiered pricing structures.

Source

A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada

Nisha Gupta et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16627

unknownCited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →